Abbott’s Tyler outlines vascular’s move to predictive modeling, diversifying trials & next-gen tech

In this special episode of AbbottTalks, recorded live from DeviceTalks West, Julie Tyler, president of Abbott's Vascular business, discusses the company's strategic evolution and commitment to comprehensive patient care, including a new technology, the Esprit BTK, intended to be released next year. Additionally, Tyler provides an insider's perspective on Abbott's integration of Cardiovascular Systems Inc., revealing how this move enhances Abbott's portfolio and positions the company at the forefront of vascular health. Tyler's vision extends beyond current interventions, aiming to leverage data and predictive modeling to improve patient outcomes and potentially reduce the need for later-stage interventions. With a patient-centric approach, Tyler also discusses the challenges and successes in diversifying clinical trial demographics and expanding global reach. This episode is a must-listen for those interested in how strategic acquisitions and a holistic health model can redefine patient care. Thank you to Resonetics for sponsoring this episode. To learn more about how Resonetics works with medical device companies, visit https://resonetics.com/. Thank you for listening to the AbbottTalks Podcast. Subscribe to this podcast on every major podcast platform.

There are no comments yet.

Please log in to write the first comment.